Triple Digit Revenue Growth and a Strong Med Tech Pipeline at Biotricity Recent NASDAQ Up-list

Triple Digit Revenue Growth and a Strong Med Tech Pipeline at Biotricity Recent NASDAQ Up-list

Good day everyone,

We are initiating coverage on Biotricity, Inc. (NASDAQ: BTCY), a medical diagnostic and consumer healthcare technology company.

Current price $3.19/share (at market close 9-10-21)

BTCY presents us with high revenue growth, a very recent NASDAQ up-list, a modest share structure, solid med tech products, and a share price that is 25% off its June high. I believe the combination of these factors positions BTCY for a near term gain in value.

On August 26, 2021, BTCY up-listed from the OTCQB Market to the NASDAQ. This brand new up-list to the NASDAQ could broaden awareness amongst investors as well as opening the door to institutional investors precluded from investing in OTC equities. In conjunction with the move to the NASDAQ the company raised $15M in a public offering of 5,000,000 shares at $3.00 per share. No warrants are indicated.

BTCY has a FYE of March 31st, so they have just completed their Q1. Let’s look at their revenue growth:

FYE 3-31-19 $398K
FYE 3-31-20 $1.4M (+260% YoY)
FYE 3-31-21 $3.3M (+240% YoY)
Revenues for Q1 ended 6-30-21 were $1.7M indicating a pro forma revenue level for FYE 3-31-22 of $7M (+ 215% YoY). These are remarkable revenue growth figures.

A look at the company stock chart indicates a June high of $4.25/share followed by a sharp drop to $2.80 in August. We believe the drop can be attributed to the public offering of shares at $3.00 at the same time. Shares can often go directly to the offering price which seems to have happened here. In the case of BTCY I believe the public offering was a good move as it creates a significant cash runway for the company as they develop new products (see below).

With the cash raise now in the rear-view mirror, the company still has a modest share structure with an estimated 45.6M shares outstanding and an estimated float of 31.3M shares. The company also indicates 8,045 preferred shares outstanding.

Analysts are bullish on BTCY performance as well:

7/1/2021 Northland Securities Initiated Coverage Outperform $7.00
7/1/2021 Noble Financial Initiated Coverage Outperform $7.00

I believe BTCY is in its infancy and is developing a trend in how we care for those patients with chronic illnesses. The concept of wearable monitoring devices that feed data to doctors in real time, without a trip to the office may change patient care. Not only is BTCY developing remarkable devices, but they are also developing devices that are easily billable to Medicare and Medicaid.

The BTCY pipeline:

Bioflux is currently the company’s flagship product. Bioflux®, is a single, integrated mobile cardiac telemetry solution that consists of a proprietary mobile ECG monitoring device and an ECG viewer software package. Bioflux® enables physicians to remotely monitor and diagnose patients with cardiovascular coronary heart disease by detecting and transmitting probable arrhythmias, along with other diagnostic heart information. Together with our proprietary software and 24/7 monitoring center, the Bioflux® system is a complete solution for remote cardiac monitoring. Bioflux is FDA approved and over 1,100 cardiologists currently use the device, monitoring 2.2 million patients.

Here is a short video that gives a look at the Bioflux device.

Biotres is a new BTCY product submitted for FDA approval on December 31, 2020. The Biotres device is a simplified version of the Bioflux device. It is designed to just continuously record the patient’s data as opposed to recording and analyzing followed by transmission in case of anomaly detection. The Biotres device is a compact version that is designed for comfort and long-term wear for lower risk patients. In this case, physicians do not expect patients to have an anomaly that would require intervention so they can use a simpler, more compact device that optimizes usability. As such the Biotres device records data continuously and uploads at the completion of the prescribed monitoring time. Biotres is expected to be available by the end of 2021.

Bioheart is a new product, and the company is now taking (pre)orders on its website for this $149 device. Bioheart is a wearable device that syncs to your smartphone for real-time data you can view on the Bioheart app. View summaries on important metrics like heart rate during rest and activity, live heart rhythm, heart rate variability, and more for advanced health tracking and performance optimization.

The company holds multiple patents for these products and two more products and services in development for future release. The combination of BTCY wearable devices and IoT allows doctors to monitor patients in real time without the need to send them to outside sources for monitoring. Current standards of collecting data on patients from outside sources allows for lag times that can render the data useless. BTCY aims to eliminate that lag time while providing alerts to immediate anomalies.

We want to offer this link to a video of Dr. Waqaas Al Siddiq, PhD discussing the company and more importantly giving his vision of the future of the BTCY platform and its potential to apply to other indication like, diabetes, COPD, and others.

Stay tuned for more information on BTCY and their products.

The Traders News Group


Privacy Policy and Disclaimer
Your Consent
By using our site, you consent to our online privacy policy and disclaimer.
Do we disclose any information to outside parties?
We do not sell your information to anyone. Please see our cookie policy below.
What information do we collect?
We collect information from you when you subscribe to our newsletter or fill out a form on one of our social platforms. This includes your email address and or mobile phone number.
When registering on our site, as appropriate, you may be asked to enter your: e-mail address and or mobile number.
What do we use your information for?
When we collect your email or mobile number it is used for one purpose to send you the information you requested about small cap stocks. Please read our disclaimer carefully before viewing our emails.
Your information, whether public or private, will not be sold, exchanged, transferred, or given to any other company for any reason whatsoever, other than for the express purpose of delivering the information on small cap stocks that you requested.
We send periodic emails
The email address you provide may be used to send you information, the small acp stock reports you requested, respond to inquiries, and/or other requests or questions.
How do we protect your information?
We implement a variety of security measures to maintain the safety of your personal information when you enter, submit, your email address. We use secure third parties to send email and sms messages to you.
Because we value your privacy we have taken the necessary precautions to be in compliance with the California Online Privacy Protection Act.
Online Privacy Policy Policy
This online privacy policy applies to information collected through our website and social media platforms.
Contacting Us
If there are any questions regarding this privacy policy or disclaimer you may contact us using the information below.
Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.

Please Note: TNS LLC and its employees are not a registered investment advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.

Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.
In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The owners and operators of this website have been compensated twenty one thousand five hundred dollars cash via bank wire for our distributed opinions on bcty this week. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.
TNS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA. TNS LLC is not a Broker/Dealer and does not engage in high frequency trading.